Uncategorized

A U.S. senator said a GLP-1 drug changed his life — and now he's calling for widespread access to anti-obesity medications.
In a New York Times op-ed on April 8, Sen. John Fetterman, D-Pa., wrote about his experience with Mounjaro (tirzepatide).
The injectable prescription medicine is primarily used to treat type 2 diabetes.
OZEMPIC’S HEALTH BENEFITS KEEP GROWING, BUT ARE THE RISKS WORTH IT?
Fetterman was prescribed the medication in July 2025.
“As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote.
“Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health,” he continued.
“Aches, pains and stiffness have vanished. Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years. As far as side effects, I&rsq..

A U.S. senator said a GLP-1 drug changed his life — and now he's calling for widespread access to anti-obesity medications.
In a New York Times op-ed on April 8, Sen. John Fetterman, D-Pa., wrote about his experience with Mounjaro (tirzepatide).
The injectable prescription medicine is primarily used to treat type 2 diabetes.
OZEMPIC’S HEALTH BENEFITS KEEP GROWING, BUT ARE THE RISKS WORTH IT?
Fetterman was prescribed the medication in July 2025.
“As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote.
“Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health,” he continued.
“Aches, pains and stiffness have vanished. Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years. As far as side effects, I&rsq..

A U.S. senator said a GLP-1 drug changed his life — and now he's calling for widespread access to anti-obesity medications.
In a New York Times op-ed on April 8, Sen. John Fetterman, D-Pa., wrote about his experience with Mounjaro (tirzepatide).
The injectable prescription medicine is primarily used to treat type 2 diabetes.
OZEMPIC’S HEALTH BENEFITS KEEP GROWING, BUT ARE THE RISKS WORTH IT?
Fetterman was prescribed the medication in July 2025.
“As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote.
“Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health,” he continued.
“Aches, pains and stiffness have vanished. Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years. As far as side effects, I&rsq..

A U.S. senator said a GLP-1 drug changed his life — and now he's calling for widespread access to anti-obesity medications.
In a New York Times op-ed on April 8, Sen. John Fetterman, D-Pa., wrote about his experience with Mounjaro (tirzepatide).
The injectable prescription medicine is primarily used to treat type 2 diabetes.
OZEMPIC’S HEALTH BENEFITS KEEP GROWING, BUT ARE THE RISKS WORTH IT?
Fetterman was prescribed the medication in July 2025.
“As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote.
“Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health,” he continued.
“Aches, pains and stiffness have vanished. Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years. As far as side effects, I&rsq..

A U.S. senator said a GLP-1 drug changed his life — and now he's calling for widespread access to anti-obesity medications.
In a New York Times op-ed on April 8, Sen. John Fetterman, D-Pa., wrote about his experience with Mounjaro (tirzepatide).
The injectable prescription medicine is primarily used to treat type 2 diabetes.
OZEMPIC’S HEALTH BENEFITS KEEP GROWING, BUT ARE THE RISKS WORTH IT?
Fetterman was prescribed the medication in July 2025.
“As a stroke survivor, I was interested in studies showing [Mounjaro] could significantly reduce the risk of major cardiac events,” the senator wrote.
“Even though I started taking it for my heart health, I’ve been struck by how much better it has made me feel across the board. It’s made a significant impact on my overall health,” he continued.
“Aches, pains and stiffness have vanished. Physically, I feel a decade younger, as well as clearer-headed and more optimistic than I’d been in years. As far as side effects, I&rsq..

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can increase the risk of heart attacks and strokes.
Many Americans are unaware that elevated levels of this particle — known as lipoprotein(a) or Lp(a) — are circulating in their blood.
Elevated Lp(a) cannot be modified with lifestyle changes, and has been called “one of the last untreatable frontiers of cardiovascular risk” by Cleveland Clinic, who led the study.
LOW-CARB KETO DIET MAY NOT RAISE HEART DISEASE RISK, NEW STUDY SUGGESTS
This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can “silence” the main gene responsible for synthesizing Lp(a).
(Other experimental gene therapies with a similar mechanism of action are also in development, according to Cleveland Clinic.)
The findings were published in The New England Journal of Medicine and were also presented at the annual m..

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can increase the risk of heart attacks and strokes.
Many Americans are unaware that elevated levels of this particle — known as lipoprotein(a) or Lp(a) — are circulating in their blood.
Elevated Lp(a) cannot be modified with lifestyle changes, and has been called “one of the last untreatable frontiers of cardiovascular risk” by Cleveland Clinic, who led the study.
LOW-CARB KETO DIET MAY NOT RAISE HEART DISEASE RISK, NEW STUDY SUGGESTS
This new research confirmed earlier findings showing that the experimental drug — lepodisiran, made by Eli Lilly, who funded the study — can “silence” the main gene responsible for synthesizing Lp(a).
(Other experimental gene therapies with a similar mechanism of action are also in development, according to Cleveland Clinic.)
The findings were published in The New England Journal of Medicine and were also presented at the annual m..

Martin Zubimendi’s long-term future is uncertain, as Real Madrid enter the race for the Spain international, who has been subject to strong interest from Arsenal

How the Arsenal kits in 2025/26 could look if AI was in control of the designs

How the Spurs kits in 2025/26 could look if AI was in control of the designs